NewAmsterdam Pharma Co NV
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Shareholders' Equity (Deficit)
Condensed Consolidated Statements of Shareholders' Equity (Deficit)
| (In thousands of USD, except share amounts) | Shares | Amount | Additional Paid-In Capital | Accumulated Loss | Cumulative Translation Adjustments | Total Shareholders' Equity |
|---|---|---|---|---|---|---|
| Balance at December 31, 2022 | 81,559,780 | 10,055 | 555,625 | (140,036) | 4,422 | 430,066 |
| Exercise of warrants | 208,032 | 27 | 2,671 | — | — | 2,698 |
| Share-based compensation | — | — | 7,663 | — | — | 7,663 |
| Total loss and comprehensive loss for the period | — | — | — | (42,018) | — | (42,018) |
| As at March 31, 2023 | 81,767,812 | 10,082 | 565,959 | (182,054) | 4,422 | 398,409 |
| Exercise of warrants | 541,609 | 70 | 7,444 | — | — | 7,514 |
| Exercise of stock options | 14,910 | 2 | 103 | — | — | 105 |
| Share-based compensation | — | — | 5,606 | — | — | 5,606 |
| Total loss and comprehensive loss for the period | — | — | — | (38,291) | — | (38,291) |
| As at June 30, 2023 | 82,324,331 | 10,154 | 579,112 | (220,345) | 4,422 | 373,343 |
| Exercise of warrants | 100 | 0 | 1 | — | — | 1 |
| Exercise of stock options | 145,337 | 19 | 166 | — | — | 185 |
| Share-based compensation | — | — | 5,439 | — | — | 5,439 |
| Total loss and comprehensive loss for the period | — | — | — | (47,133) | — | (47,133) |
| As at September 30, 2023 | 82,469,768 | 10,173 | 584,718 | (267,478) | 4,422 | 331,835 |
| Balance at December 31, 2023 | 82,469,768 | 10,173 | 590,771 | (316,973) | 4,422 | 288,393 |
| Issuance of Ordinary Shares and Pre-Funded Warrants, net of issuance costs | 5,871,909 | 759 | 189,207 | — | — | 189,966 |
| Exercise of warrants | 926,698 | 121 | 19,674 | — | — | 19,795 |
| Exercise of stock options | 452,461 | 60 | (609) | — | — | (549) |
| Share-based compensation | — | — | 7,965 | — | — | 7,965 |
| Total loss and comprehensive loss for the period | — | — | — | (93,767) | — | (93,767) |
| As at March 31, 2024 | 89,720,836 | 11,113 | 807,008 | (410,740) | 4,422 | 411,803 |
| Exercise of warrants | 294,521 | 38 | 6,268 | — | — | 6,306 |
| Share-based compensation | — | — | 8,337 | — | — | 8,337 |
| Total loss and comprehensive loss for the period | — | — | — | (39,007) | — | (39,007) |
| As at June 30, 2024 | 90,015,357 | 11,151 | 821,613 | (449,747) | 4,422 | 387,439 |
| Exercise of Pre-Funded Warrants | 2,105,248 | 279 | (279) | — | — | — |
| Exercise of stock options | 45,000 | 5 | 53 | — | — | 58 |
| Share-based compensation | — | — | 8,012 | — | — | 8,012 |
| Total loss and comprehensive loss for the period | — | — | — | (16,647) | — | (16,647) |
| As at September 30, 2024 | 92,165,605 | 11,435 | 829,399 | (466,394) | 4,422 | 378,862 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.